Actemra IL-6R Neutralisation Bioassays

Bioassays provide the means to directly assess the fundamental biological activity of Actemra/RoActemra (tocilizumab), and as such signify a key component of a product characterization study.  Our extensive experience in the development of bioassays for the assessment of a wide range of monoclonal antibody products has allowed us to develop cell-based assays to measure the blocking activity of Actemra/RoActemra and tocilizumab biosimilar products for use in clone selection, process development, characterization and similarity studies.  We offer assays that characterize both classical and trans mechanisms of signalling.

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.